Zozaya GA, Huerta LJG, López PGT, García-Benítez L

Language: Spanish
References: 25
Page: 8-17
PDF size: 220.23 Kb.

ABSTRACT

Introduction: Allergic rhinitis is a disease characterized by symptoms such as rhinorrhea, nasal itching, nasal congestion and sneezing. The treatment includes nasal steroids, antihistamines, nasal decongestants and immunotherapy. This last treatment has the property of modifying the natural course of the disease. Objective: To know the time that elapses for the improvement of the symptoms of the patients after the beginning of the immunotherapy. Material and methods: This is a retrospective study in which patients aged 1-17 years were included with treatment of immunotherapy secondary to allergic rhinitis, in the period from 2014 to 2015. The improvement time was defined as the time elapsed from the beginning of the immunotherapy until the decrease in the severity or absence of symptoms. Results: A total of 100 patients with an average age of 10 years were included. The treatment time was from 2 to 84 months with an average of 27 months. It was found that 75% of the patients who received immunotherapy presented improvement according to the severity classification of allergic rhinitis. The average time to symptom improvement was 7.5 months. Conclusion: The time of clinical improvement of patients with allergic rhinitis who received immunotherapy was relatively lower than that reported in the world literature.

REFERENCES

1. Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica. [Artículo] (México, D.F.), Imbiomed; 2000, p. 33.

2. Valenzuela SA. Valoración y eficacia de un extracto de alternarnata en pacientes pediátricos con enfermedades alérgicas respiratorias, modificación de parámetros in vitro e in vivo. [Tesis doctoral]. [Editorial de la Universidad de Granada]. Granada España. 2007. p. 214.

3. Wonca Expert Panel. WHO, GALEN, allergen. Management of allergic rhinitis and its impact in asthma. [Pocket Guide ARIA]. [USA]: MCR, 2007, p. 8.

4. López GP. Prevalencia de las enfermedades alérgicas en la Ciudad de México. [Artículo] [México, D.F.] Revista Alergia México; 2009; 56 (3): 72-79.

5. Beasley R, Bousquet J, Von Motius. Worlwide variation in prevalence of symptoms of asthma, allergic rhinoconjuntivitis and atopic eczema. ISAAC. Lancet. 1998; 351 (9111): 12225-12232.

6. Larenas LD. Rinitis alérgica ARIA 2014. México, Colegio Mexicano de Inmunología Clínica y Alergia, Sociedad Latinoamericana de Alergia, Asma e Inmunología. Revista Alergia México. 2014; 61 (Supl. 1): 123.

7. Martínez SA. Inmunoterapia sublingual en la rinitis alérgica estacional revisión de 30 pacientes. [Investigación clínica]. [Hospital Universitario de Getafe. Madrid España. Acta Otorrinolaringol. 2005; 56: 112-115.

8. Negro JM, Rodríguez PR. Rinitis alérgica. Revista Actualizaciones el Médico. [España] Actualizaciones el médico. 2006, p. 34.

9. Constante MK. Análisis estadístico de la morbilidad infantil, caso del área del hospital del niño Francisco Bustamante 2000. [Tesis] [Escuela Superior Politécnico Nacional. 2000]

10. Rodríguez MM. Rinitis alérgica. Madrid, España. Sistema Nacional de Salud. 2000; 24 (1).

11. Comité Nacional de Alergia, Neumología y Otorrinolaringología. Consenso Nacional de Rinitis Alérgica en Pediatría. [Argentina]. Sociedad Argentina de Pediatría. 2009; 107 (1): 67-81. p. 15.

12. Gobierno Federal México. Diagnóstico y tratamiento de rinitis alérgica. [Guía Práctica Clínica]. México, 2009, p. 38.

13. Ricardo SJS. Prevalencia de alérgenos en pacientes con rinitis alérgica, atendidos en el Hospital Central Militar. [Investigación]. México. An ORL Mex. 2012; 57 (1): 7.

14. Cid del Prado. Estudio aerobiológico de pólenes anemófilos en la Ciudad de Toluca, México. Revista Alergia México. 2015; 62: 8-14.

15. Baena PM. Guía de seguimiento farmacoterapéutico sobre rinitis alérgica. [Internet]. Granada España; Universidad de Granada. [15 Enero 2016]. Disponible en: http://www.ugr.es/~cts131/esp/guias/GUIA_RINITIS.pdf

16. British Society for Allergy and Clinical Immunology. Rhinitis management guidelines. Available in: http://www.eguidelines.co.uk/

17. Meltzer E, Jalowayski A. Nasal cytogram in clinical practice. Am J Rhinology. 1988; 2 (2): 47-54.

18. Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med. 2015; 372 (5): 456-463.

19. Colegio Mexicano de Inmunología Clínica y Alergia. Sociedad Latinoamericana de Alergia, Asma e Inmunología. ARIA Mexico 2014. Revista Alergia. 2014; 61-1: 123.

20. Scadding GK, Kariyawasam H, Scadding G. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. (Revised Edition 2017; First edition 2007). London England. 2017.

21. Moote W, Kim H, Ellis AK. Allergen‑specific immunotherapy. Allergy Asthma Clin Immunol. 2018; 14 (Suppl 2): 53. London 2018.

22. Yu Guo, Yanqing Li, Li Hu. A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis. Am J Rhinol Allergy. 2017; 31 (4): 42-47.

23. Wang ZX, SHI H. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis. J Huazhong Univ Sci Techno Med Sci. 2017; 37 (3): 407-411.

24. Cvetkovski B, Tan R, Kritikos V, Yan K, Azzi E, Srour P et al. A patient-centric analysis to identify key influences in allergic rhinitis management. NPJ Prim Care Respir Med. 2018; 28 (1): 34.

25. Désirée Larenas L, José Antonio Ortega M, Blanca del Río-Navarro.y cols. Guía Mexicana de Práctica Clínica de Inmunoterapia 2011. Colegio Mexicano de Inmunología Clínica y Alergia, AC y de la Sociedad Latinoamericana de Alergia, Asma e Inmunología. Revista de Alergia Mexico . Elsevier.2011. 51 p.